The answer is "it should be," says columnist. That way, sickle cell patients could receive the support that they need.

Standard treatments can significantly lower the risk of stroke in children with sickle cell anemia, according to a review of ...

The Phase 1/2 CLIMB-SCD-121 trial (NCT03745287) is currently evaluating the safety and effectiveness of a single infusion of CTX001 in adults up to age 35 with severe SCD. Two patients have been dosed ...

I have always been a passionate advocate for sickle cell disease prevention, sometimes even prioritizing it over advocating for a cure. I envision a world where no child has to suffer the ...

The incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease (SCD) is elevated during January to March, a large nationwide, retrospective study in the U.S.

Acute chest syndrome (ACS), a form of lung injury associated with sickle cell disease (SCD), is driven by the abnormal activation of a part of the immune system known as the complement cascade, a ...

In my previous column, I shared my suggestions on the preparations you should consider before taking a trip with sickle cell. The environment inside an airplane is not ideal for our bodies. On a ...

More than 1 in 3 children and adolescents with sickle cell disease (SCD) develop retinopathy, or damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye, ...

The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment Oxbryta (voxelotor) — withdrawn from the market ...

The Centers for Medicare & Medicaid Services (CMS) has announced that 33 states, along with the District of Columbia and Puerto Rico, have agreed to participate in the Cell and Gene Therapy (CGT) ...

The first participant with sickle cell disease (SCD) has been dosed in a clinical trial of HBI-002, an experimental, low-dose, oral liquid formulation of carbon monoxide being developed by Hillhurst ...

The first sickle cell disease (SCD) patient has been enrolled in a Phase 1b clinical trial evaluating iadademstat, Oryzon Genomics‘ investigational oral therapy designed to boost fetal hemoglobin (HbF ...